Improving Transparency in Pharmaceutical Systems : Strengthening Critical Decision Points Against Corruption
This study presents a diagnostic framework and methodology to evaluate a pharmaceutical system s vulnerability to corruption and to determine which corrupt practices can have a major impact on the system s ultimate efficiency. We thus provide: (a)...
| Main Authors: | , , |
|---|---|
| Format: | Working Paper |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2014
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2002/10/20201536/improving-transparency-pharmaceutical-systems-strengthening-critical-decision-points-against-corruption http://hdl.handle.net/10986/20426 |
| Summary: | This study presents a diagnostic
framework and methodology to evaluate a pharmaceutical
system s vulnerability to corruption and to determine which
corrupt practices can have a major impact on the system s
ultimate efficiency. We thus provide: (a) a systematic and
quantifiable assessment of the extent to which a country s
pharmaceutical system is vulnerable to corrupt practices;
and (b) the identification of potential actions to increase
the system s resistance to corruption, and ultimately,
improve access of the population to good quality, essential
medicines. The diagnostic framework and methodology permit
users to identify key decision points in the pharmaceutical
supply and distribution system (registration, selection,
procurement, distribution, service delivery and use); assess
the extent to which a country s current policies and
practices at each of these key decision points make the
system vulnerable to corruption; and understand the range of
options that could reduce this vulnerability. This
diagnostic tool has been designed for use by World Bank
health specialists involved in health lending operations
that include pharmaceutical components, and their national
counterparts to help them identify points of vulnerability
in the pharmaceutical system, address these points, and thus
help ensure that pharmaceutical expenditures are maximized.
While developed in the context of the health systems of
Latin America and the Caribbean (and implemented in a pilot
study in Costa Rica), the methodology can be modified with
ease so that it is applicable to other regions. |
|---|